Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
Más filtros













Intervalo de año de publicación
1.
Pediatrics ; 147(3)2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33597285

RESUMEN

PSTPIP1-associated myeloid-related proteinemia inflammatory (PAMI) syndrome is a rare early-onset autoinflammatory disease associated with various hematologic findings, including chronic neutropenia and pancytopenia. We report a unique case of PAMI syndrome in a toddler with transfusion-dependent hemolytic anemia, hepatosplenomegaly, failure to thrive, developmental delay, and multiple malformations. Because of acute inflammatory-driven decompensation, anakinra was started with dramatic improvement of both the hematologic and neurologic involvement. A customized next-generation sequencing panel later identified a de novo pathogenic variant in the PSTPIP1 gene, confirming the diagnosis. Our case illustrates the broad spectrum of phenotypes associated with PAMI syndrome, which should be considered in any case of unexplained cytopenias associated with autoinflammatory stigmata. It is also one of the few reports of neurologic involvement in PSTPIP1-associated inflammatory diseases. Increased awareness of this rare disease and early performance of genetic testing can correctly diagnose PAMI syndrome and prevent disease complications.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/genética , Proteínas del Citoesqueleto/genética , Hemólisis , Proteína Antagonista del Receptor de Interleucina 1/uso terapéutico , Enfermedades Raras/genética , Anomalías Múltiples , Anemia Hemolítica Congénita/sangre , Anemia Hemolítica Congénita/tratamiento farmacológico , Atrofia/diagnóstico por imagen , Atrofia/tratamiento farmacológico , Transfusión Sanguínea , Encéfalo/diagnóstico por imagen , Encéfalo/patología , Proteína C-Reactiva/análisis , Enfermedad Crónica , Discapacidades del Desarrollo/tratamiento farmacológico , Facies , Insuficiencia de Crecimiento/tratamiento farmacológico , Fiebre/orina , Hemólisis/efectos de los fármacos , Hepatomegalia/diagnóstico por imagen , Hepatomegalia/tratamiento farmacológico , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Lactante , Linfadenopatía/tratamiento farmacológico , Masculino , Pancitopenia , Fenotipo , Enfermedades Raras/sangre , Enfermedades Raras/tratamiento farmacológico , Recuento de Reticulocitos , Esplenomegalia/diagnóstico por imagen , Esplenomegalia/tratamiento farmacológico , Síndrome
2.
Int J Mol Sci ; 21(3)2020 Feb 06.
Artículo en Inglés | MEDLINE | ID: mdl-32041196

RESUMEN

Patients with hereditary hemochromatosis and non-transfusion-dependent hereditary anemia develop predominantly liver iron-overload. We present a unique method allowing quantification of liver iron retention in humans during first-pass of 59Fe-labeled iron through the portal system, using standard ferrokinetic techniques measuring red cell iron uptake after oral and intravenous 59Fe administration. We present data from patients with iron deficiency (ID; N = 47), hereditary hemochromatosis (HH; N = 121) and non-transfusion-dependent hereditary anemia (HA; N = 40). Mean mucosal iron uptake and mucosal iron transfer (±SD) were elevated in patients with HH (59 ± 18%, 80 ± 15% respectively), HA (65 ± 17%, 74 ± 18%) and ID (84 ± 14%, 94 ± 6%) compared to healthy controls (43 ± 19%, 64 ± 18%) (p < 0.05) resulting in increased iron retention after 14 days compared to healthy controls in all groups (p < 0.01). The fraction of retained iron utilized for red cell production was 0.37 ± 0.17 in untreated HA, 0.55 ± 0.20 in untreated HH and 0.99 ± 0.22 in ID (p < 0.01). Interestingly, compared to red blood cell iron utilization after oral iron administration, red blood cell iron utilization was higher after injection of transferrin-bound iron in HA and HH. Liver iron retention was considerably higher in HH and HA compared to ID. We hypothesize that albumin serves as a scavenger of absorbed Fe(II) for delivering albumin-bound Fe(III) to hepatocytes.


Asunto(s)
Anemia Hemolítica Congénita/tratamiento farmacológico , Anemia Ferropénica/tratamiento farmacológico , Hemocromatosis/tratamiento farmacológico , Radioisótopos de Hierro/administración & dosificación , Hígado/química , Administración Intravenosa , Administración Oral , Adolescente , Adulto , Anciano , Anemia Hemolítica Congénita/metabolismo , Anemia Ferropénica/metabolismo , Estudios de Casos y Controles , Femenino , Hemocromatosis/metabolismo , Humanos , Radioisótopos de Hierro/farmacocinética , Masculino , Persona de Mediana Edad , Albúmina Sérica Humana/metabolismo , Transferrina/metabolismo , Adulto Joven
4.
Nephrol Ther ; 11(7): 569-72, 2015 Dec.
Artículo en Francés | MEDLINE | ID: mdl-26404944

RESUMEN

Bartonella quintana is a facultative intracellular bacteria responsible of negative blood culture endocarditis whose diagnosis is often delayed. The occurrence of renal involvement has been exceptionally described in this context. We report the case of a 54-year-old man presenting with Bartonella quintana endocarditis complicated by proliferative glomerulonephritis with acute kidney injury and erythroblastopenia.


Asunto(s)
Anemia Hemolítica Congénita/microbiología , Bartonella quintana , Endocarditis Bacteriana/microbiología , Glomerulonefritis/microbiología , Fiebre de las Trincheras/microbiología , Lesión Renal Aguda/diagnóstico , Lesión Renal Aguda/tratamiento farmacológico , Lesión Renal Aguda/microbiología , Anemia Hemolítica Congénita/diagnóstico , Anemia Hemolítica Congénita/tratamiento farmacológico , Antibacterianos/uso terapéutico , Bartonella quintana/aislamiento & purificación , Glomerulonefritis/diagnóstico , Glomerulonefritis/tratamiento farmacológico , Humanos , Riñón/patología , Masculino , Persona de Mediana Edad , Fiebre de las Trincheras/diagnóstico , Fiebre de las Trincheras/tratamiento farmacológico
5.
Einstein (Säo Paulo) ; 11(4): 528-532, out.-dez. 2013. ilus, tab
Artículo en Portugués | LILACS | ID: lil-699869

RESUMEN

Relatar um caso de sobrecarga de ferro secundária à xerocitose, uma doença rara, em uma adolescente, diagnosticada por meio de ressonância magnética em T2*. Relatamos o caso de uma paciente sintomática com xerocitose, nível de ferritina de 350ng/mL e sobrecarga de ferro cardíaca significativa. Ela foi diagnosticada por ressonância magnética em T2* e recebeu terapia de quelação. Análise por ectacitometria confirmou o diagnóstico de xerocitose hereditária. Na sequência, a ressonância magnética em T2* demonstrou resolução completa da sobrecarga de ferro em vários órgãos e novo ecocardiograma revelou resolução completa das alterações cardíacas anteriores. A paciente permanece em terapia de quelação. Xerocitose é uma desordem genética autossômica dominante rara, caracterizada por estomatocitose desidratada. O paciente pode apresentar fadiga intensa e sobrecarga de ferro. Sugerimos o uso regular de ressonância magnética em T2* para o diagnóstico e controle da resposta à quelação de ferro em xerocitose e acreditamos que o exame pode ser útil também em outras anemias hemolíticas que necessitam de transfusões.


To report a case of iron overload secondary to xerocytosis, a rare disease in a teenager, diagnosed, by T2* magnetic resonance imaging. We report the case of a symptomatic patient with xerocytosis, a ferritin level of 350ng/mL and a significant cardiac iron overload. She was diagnosed by T2* magnetic resonance imaging and received chelation therapy Ektacytometric analysis confirmed the diagnosis of hereditary xerocytosis. Subsequent T2* magnetic resonance imaging demonstrated complete resolution of the iron overload in various organs, as a new echocardiography revealed a complete resolution of previous cardiac alterations. The patient remains in chelation therapy. Xerocytosis is a rare autosomal dominant genetic disorder characterized by dehydrated stomatocytosis. The patient may present with intense fatigue and iron overload. We suggest the regular use of T2* magnetic resonance imaging for the diagnosis and control of the response to iron chelation in xerocytosis, and we believe it can be used also in other hemolytic anemia requiring transfusions.


Asunto(s)
Adolescente , Femenino , Humanos , Anemia Hemolítica Congénita/diagnóstico , Hidropesía Fetal/diagnóstico , Sobrecarga de Hierro/diagnóstico , Anemia Hemolítica Congénita/complicaciones , Anemia Hemolítica Congénita/tratamiento farmacológico , Terapia por Quelación , Deferoxamina/uso terapéutico , Hidropesía Fetal/tratamiento farmacológico , Sobrecarga de Hierro/tratamiento farmacológico , Sobrecarga de Hierro/etiología , Imagen por Resonancia Magnética , Sideróforos/uso terapéutico
6.
Einstein (Sao Paulo) ; 11(4): 528-32, 2013 Dec.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-24488397

RESUMEN

To report a case of iron overload secondary to xerocytosis, a rare disease in a teenager, diagnosed, by T2* magnetic resonance imaging. We report the case of a symptomatic patient with xerocytosis, a ferritin level of 350ng/mL and a significant cardiac iron overload. She was diagnosed by T2* magnetic resonance imaging and received chelation therapy Ektacytometric analysis confirmed the diagnosis of hereditary xerocytosis. Subsequent T2* magnetic resonance imaging demonstrated complete resolution of the iron overload in various organs, as a new echocardiography revealed a complete resolution of previous cardiac alterations. The patient remains in chelation therapy. Xerocytosis is a rare autosomal dominant genetic disorder characterized by dehydrated stomatocytosis. The patient may present with intense fatigue and iron overload. We suggest the regular use of T2* magnetic resonance imaging for the diagnosis and control of the response to iron chelation in xerocytosis, and we believe it can be used also in other hemolytic anemia requiring transfusions.


Asunto(s)
Anemia Hemolítica Congénita/diagnóstico , Hidropesía Fetal/diagnóstico , Sobrecarga de Hierro/diagnóstico , Adolescente , Anemia Hemolítica Congénita/complicaciones , Anemia Hemolítica Congénita/tratamiento farmacológico , Terapia por Quelación , Deferoxamina/uso terapéutico , Femenino , Humanos , Hidropesía Fetal/tratamiento farmacológico , Sobrecarga de Hierro/tratamiento farmacológico , Sobrecarga de Hierro/etiología , Imagen por Resonancia Magnética , Sideróforos/uso terapéutico
10.
Am J Hematol ; 76(4): 378-82, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15282673

RESUMEN

A boy presented at age 4 years with severe congenital hemolytic anemia characterized by highly elevated reticulocyte count (30-50%) and prominent basophilic stippling. Hb had been 4 g/dL at age 7 months. The patient was on a monthly transfusion regimen up to the age of 7 years, when he underwent splenectomy. After removal of the spleen, his Hb stabilized at 11 g/dL. No abnormal pattern was detected in hemoglobin electrophoresis at pH 9 and 6. In-vitro globin synthesis revealed the presence of an abnormal beta-chain in front of the gamma-chain. The beta(A)/beta(X) ratio was 0.77 at 30 min and 0.74 at 2 hr of incubation. Molecular analysis revealed that the patient had GCC-->GAC alteration at codon 27 (beta27(B9)Ala-->Asp) causing the abnormal hemoglobin Volga. The beta-cDNA derived from the beta-Hb Volga allele could be differentiated from HbA beta-cDNA on silver-stained gel. No imbalance in the mRNA of beta(A)/beta(Hb Volga) ratio was observed.


Asunto(s)
Anemia Hemolítica Congénita/genética , Hemoglobinas Anormales/genética , Adulto , Anemia Hemolítica Congénita/sangre , Anemia Hemolítica Congénita/tratamiento farmacológico , Anemia Hemolítica Congénita/cirugía , Electroforesis de las Proteínas Sanguíneas , Preescolar , Codón/genética , Terapia Combinada , Deferoxamina/uso terapéutico , Desoxirribonucleasas de Localización Especificada Tipo II , Femenino , Globinas/genética , Hemoglobinas Anormales/aislamiento & purificación , Humanos , Quelantes del Hierro/uso terapéutico , Masculino , Polimorfismo de Longitud del Fragmento de Restricción , Embarazo , Complicaciones Hematológicas del Embarazo/etiología , Recuento de Reticulocitos , Tinción con Nitrato de Plata , Esplenectomía , Trombosis/etiología , Turquía
11.
Pediatr Hematol Oncol ; 18(4): 279-82, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11400653

RESUMEN

The authors report the use of high-dose recombinant erythropoietin (r-HuEPO) in a full-term newborn baby with severe postnatal rhesus hemolytic anemia (RHA). Hemoglobin (Hb) value and reticulocyte count at day 13 of life were 59 g/L and 234 x 10(9)/L, respectively. Three days after the r-HuEPO (870 U/kg/d) administration, reticulocyte count had increased more than 4-fold and Hb rose to 73 g/L. r-HuEPO was gradually decreased after 18 days of treatment. No major side effect was observed. In selected cases of severe anemia due to hemolytic disorders, transfusions may be avoided by the use of high doses of r-HuEPO.


Asunto(s)
Anemia Hemolítica Congénita/tratamiento farmacológico , Eritropoyetina/administración & dosificación , Isoinmunización Rh/sangre , Anemia Hemolítica Congénita/etiología , Femenino , Hemoglobinas/metabolismo , Humanos , Recién Nacido , Proteínas Recombinantes , Recuento de Reticulocitos , Isoinmunización Rh/complicaciones , Factores de Tiempo , Resultado del Tratamiento
13.
Farmakol Toksikol ; 49(5): 101-2, 1986.
Artículo en Ruso | MEDLINE | ID: mdl-3770161

RESUMEN

A clinical trial of the action of glucocorticoids, iron preparation and vitamin B12 in a combined treatment on hematological parameters in childhood hereditary hemolytic anemia was performed. The drugs were found to exert no effect on hematological parameters in the period of hemolytic crises. In aregeneratory crises prescribing short courses of glucocorticoids and vitamin B12 produced a good clinicohematological effect.


Asunto(s)
Anemia Hemolítica Congénita/sangre , Anemia Hemolítica Congénita/tratamiento farmacológico , Niño , Quimioterapia Combinada , Glucocorticoides/uso terapéutico , Humanos , Hierro/sangre , Hierro/uso terapéutico , Vitamina B 12/sangre , Vitamina B 12/uso terapéutico
14.
Clin Chim Acta ; 141(2-3): 93-100, 1984 Aug 31.
Artículo en Inglés | MEDLINE | ID: mdl-6091951

RESUMEN

We evaluated the glycolytic intermediate concentrations from the erythrocytes of a patient with hereditary pyrimidine 5'-nucleotidase (P5'N) deficiency. Conclusive evidence for a metabolic block was not found. We evaluated the effects of the pyrimidine (cytidine and uridine) tri- and diphosphate nucleotides (CTP, CDP, UTP, UDP) and the choline and ethanolamine derivatives of CDP (CDP-choline, CDP-ethanolamine) on the activities of key enzymes of the Embden-Meyerhof pathway. CTP and UTP inhibited fructose-6-phosphate competitively for phosphofructokinase and phosphoenolpyruvate competitively for pyruvate kinase. In both cases, the Ki of the pyrimidine nucleotide and Km of the glycolytic substrate were above their intraerythrocytic concentrations. CTP was a competitive inhibitor of ADP for pyruvate kinase with a Ki near its intraerythrocytic concentration. CDP-choline and CDP-ethanolamine had no effect on the activities of Embden-Meyerhof or pentose phosphate shunt enzymes. Thus, the nature of the hemolytic anemia in hereditary P5'N deficiency remains enigmatic.


Asunto(s)
Anemia Hemolítica Congénita/enzimología , Glucólisis/efectos de los fármacos , Nucleotidasas/deficiencia , Vía de Pentosa Fosfato/efectos de los fármacos , Nucleótidos de Pirimidina/farmacología , 5'-Nucleotidasa , Adenosina Trifosfato/farmacología , Anemia Hemolítica Congénita/tratamiento farmacológico , Unión Competitiva , Citidina Trifosfato/farmacología , Eritrocitos/efectos de los fármacos , Eritrocitos/enzimología , Glucosafosfato Deshidrogenasa/antagonistas & inhibidores , Humanos , Fosfofructoquinasa-1/antagonistas & inhibidores , Fosfogluconato Deshidrogenasa/sangre , Fosfoglicerato Quinasa/sangre , Piruvato Quinasa/antagonistas & inhibidores , Uridina Trifosfato/farmacología
18.
Hosp Pract ; 12(10): 79-85, 1977 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-578501

RESUMEN

Antioxidant effect of vitamin E averts hemolytic anemia in low-birthweight infants fed formula rich in polyunsaturated fatty acids and iron. Tocopherol supplementation has also been shown to decrease the incidence and severity of retrolental fibroplasia and the development of bronchopulmonary dysplasia. Although the vitamin lowers platelet hyperaggregability, its role as an antithrombotic agent is still unclear.


Asunto(s)
Vitamina E/fisiología , Anemia Hemolítica Congénita/tratamiento farmacológico , Anemia Hemolítica Congénita/etiología , Antioxidantes , Ácidos Grasos Insaturados/metabolismo , Fibrinolíticos , Humanos , Fenómenos Fisiológicos Nutricionales del Lactante , Recién Nacido , Enfermedades del Prematuro/tratamiento farmacológico , Claudicación Intermitente/tratamiento farmacológico , Agregación Plaquetaria/efectos de los fármacos , Síndrome de Dificultad Respiratoria del Recién Nacido/tratamiento farmacológico , Retinopatía de la Prematuridad/tratamiento farmacológico , Vitamina E/metabolismo , Vitamina E/uso terapéutico , Deficiencia de Vitamina E/complicaciones , Deficiencia de Vitamina E/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA